Answer:
SNPs have shown that only 0.1 % of DNA sequences are different in the human genome between different individuals, thereby all the inherited phenotypic variation observed in our species is associated with only 0.1 % of differences at the genome level
Explanation:
Haplotypes are block-like sequences of DNA that are inherited together due to low recombination rates. Moreover, single-nucleotide polymorphism (SNP) mapping is a very useful methodology used to map the site of SNP mutations (i.e., SNP variants). In this regard, it has been observed that there are approximately 10 million common SNPs in the human genome. These SNPs contribute to the wide range of phenotypic variation observed in human populations for different traits (e.g., eye color, hair, weight, height, etc). Moreover, researchers have determined that SNPs can be clustered into haplotypes, thereby haplotypes can be accurately sampled by as few as approx. 300,000 selected SNPs, which are sufficient to represent all of the genetic variation across different human genomes.
A primary consumer because the mouse eats grains or producers
1. Photosynthesis produces two products, glucose and oxygen.
2. Respiration will take the products of photosynthesis and convert them into carbon dioxide and water.
Answer:
Explanation:
The more similar the two species are, the more their niche overlaps and the more competition there is.
<em>The most interesting results obtained in animal models of passive immunotherapies developed according to the “amyloid-beta cascade hypothesis” and the “Tau hypothesis” are monoclonal antibodies that directly or indirectly target Aβ plaques or neurofibrillary tangles. Unfortunately, these therapeutic antibodies cannot replicate their promising effects on humans at the clinical phase. Despite this, we still hope to learn from these failures and to explore new pathways. The great effects obtained in animals with passive immunotherapy suggest that this technology may be an important key to curative treatment. The remaining challenge is to find a way to achieve the same encouraging results for humans. Alzheimacy expects to join hands with global partners to focus on the development of therapeutic antibodies for Alzheimer’s disease (AD) and continue to fight against this disease.</em>
<em>https://www.creativebiomart.net/alzheimacy/therapeutics/therapeutic-antibody/</em>
Controls the movement of substances in and out of cells<span>. The basic </span>function<span> of the </span>cell membrane<span> is to protect the </span>cell<span> from its surroundings.
</span>
